Objectives: The aim of this study was to determine the occurrence of extended-spectrum b-lactamase (ESBL)-producing Escherichia coli at an equine clinic and a horseback riding centre, and to discuss the impact of antimicrobial treatment on resistance selection.
Introduction
Escherichia coli is a common commensal bacterial species that colonizes the gastrointestinal tracts of both humans and animals. Antibiotic-resistant commensal E. coli occur with different frequencies in human and animal populations, and in the environment. Human patients in hospitals and long-term care facilities frequently develop nosocomial infections, often caused by antibiotic -resistant E. coli clones. 1 Similarly, an increased frequency of antibiotic-resistant E. coli occurrence has been detected in horse faeces in connection with hospitalization and antimicrobial treatment of horses. 2 Medication of both humans and animals with b-lactam antibiotics, particularly third-and fourth-generation cephalosporins, underlies the selection of extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae, which are among common causative agents of nosocomial infections. 3 Among these, the proportion of CTX-M b-lactamase producers has increased within the last few years. 4 Genes encoding for ESBLs are often parts of integrons, transposons and/or plasmids, and, in the case of multiresistant strains of enterobacteria, these transposable elements often harbour structurally unrelated resistance genes. This enables their co-selection, e.g. by sulphonamides, tetracyclines or aminoglycosides. 5 Another antibiotic resistance mechanism that is recently on the increase in enterobacteria is resistance to fluoroquinolones determined by plasmid-mediated qnr genes. 6 Increased selection of ESBL producers among family members of the Enterobacteriaceae can be expected when using cephalosporins or, by co-selection, even when using # The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2011; 66: 757 -764 doi:10.1093/jac/dkq500 Advance Access publication 25 January 2011 other groups of antimicrobial substances for therapy in horses. As evidenced by recently published findings of ESBL-producing E. coli and Klebsiella pneumoniae in horses in the Netherlands, 3 it will be necessary to consider ESBL-positive enterobacteria as potential aetiological agents of nosocomial infections in equine clinics.
The aim of this study was to detect the occurrence of antibiotic -resistant E. coli in faeces of hospitalized horses and hospital staff, flies and environmental samples from the university equine clinic and from a horseback riding centre, with an emphasis on E. coli strains producing ESBLs. The equine clinic and horseback riding centre were selected for the study because of two serious cases of E. coli infection and their differing antibiotic policies. A case of metritis in one mare caused by multiresistant E. coli was diagnosed at the equine clinic, and a case of sepsis in newborn twin foals was demonstrated at the riding centre. Further goals of this work were to discuss the impact of antimicrobial treatment on the selection of ESBL -producing and fluoroquinolone-resistant E. coli, and to evaluate the likelihood of transmission and survival of ESBL -producing E. coli isolates in the conditions of the clinic and riding centre.
Materials and methods

Equine clinic
The equine clinic is located on the campus of the University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic. It has been in service since 2000 and has 50 boxes available for the hospitalization of horses. This establishment administers treatment services for .1000 horses per year. The annual usage of antimicrobial substances in 2009 was as follows: procaine benzylpenicillin +streptomycin, 1898 defined daily doses per adult horse (DDDs); enrofloxacin, 594 DDDs; metronidazole, 495 DDDs; gentamicin, 502 DDDs; trimethoprim+sulfadiazine, 384 DDDs; cefquinome, 93 DDDs; marbofloxacin, 69 DDDs; oxytetracycline, 48 DDDs; rifampicin, 17 DDDs; clarithromycin, 9 DDDs; cefazolin, 2 DDDs; and penicillin G, 2 DDDs. Data for 2009 are representative for the year 2007-08, when the samples were taken. A case of metritis in one mare caused by multiresistant E. coli (ESBL negative) was diagnosed at the equine clinic on 6 June 2007. In subsequent screening tests, faecal samples from hospitalized horses, rectal swab samples from clinic staff, environmental samples from the stables (biofilm smears from the waterers) and samples of flies (Musca domestica) were taken (Table 1 ). An ESBL-positive E. coli strain isolated from a wound of a horse hospitalized in this clinic was included in the examination.
Horseback riding centre
The monitored horseback riding centre is located in the south-east of the Czech Republic, in the municipal territory of the town of Korycany, 60 km from Brno. The riding centre has no relation to the equine clinic. At the time of sampling, 35 horses were kept at the centre. Horses were stabled in boxes in two stables. The antibiotic therapy of the horses was evaluated over 2007 and 2008. According to the data provided by a veterinarian, antibiotics were administered only in the course of castrations and respiratory infections, and to treat flesh wounds. Benzylpenicillin +streptomycin (76 DDDs), trimethoprim+ sulfadiazine (7 DDDs), oxytetracycline (5 DDDs) and first-generation cephalosporins (1/2 DDDs) were used. A case of sepsis in newborn twin foals was demonstrated here in April 2008. These twin foals were treated with the fourth-generation cephalosporin cefquinome. One of the foals had to be euthanized due to progressive general infection on 14 April 2008. The necropsy and subsequent cultivation examination proved E. coli sepsis caused by ESBL-producing E. coli (sample no. 62510). Within this context, three subsequent samplings were taken, including faecal samples from horses (including the mother of the antibiotic-treated twins), environmental smears from boxes (waterers), samples of flies (M. domestica) and a rectal swab of a cat (Table 1) . Dolejska et al.
Isolation of ESBL-producing E. coli and antibiotic susceptibility testing
Samples were enriched in MacConkey broth and cultivated on MacConkey agar with cefotaxime (2 mg/L). Selected isolates (1 isolate per 1 sample) were examined for the production of ESBL using the double-disc synergy test 7, 8 and identified by the API 10S test kit (bioMérieux, France). The disc diffusion method 9 was used to test for susceptibility to 12 selected antimicrobial substances: ampicillin (10 mg); streptomycin (30 mg); sulphonamides compound (300 mg); tetracycline (30 mg); sulfamethoxazole/trimethoprim (23.75/1.25 mg); chloramphenicol (30 mg); cefalotin (30 mg); nalidixic acid (30 mg); ceftazidime (30 mg); gentamicin (10 mg); amoxicillin/clavulanic acid (30 mg); and ciprofloxacin (5 mg). In horses with proven excretion of ESBL-producing E. coli, the concentration of cefotaxime-resistant E. coli per gram of faeces was determined. For this purpose, the faecal samples were weighed, homogenized in phosphate-buffered saline, 10 times diluted and then cultivated on MacConkey agar with cefotaxime (2 mg/L). ESBL production was proven in cefotaxime-resistant colonies using a double-disc synergy test.
PCR and testing of antibiotic resistance genes
The genes responsible for the ESBL phenotype (bla TEM , bla SHV and bla CTX-M ) were identified by PCR (Table S1 , available as Supplementary data at JAC Online), and the products were sequenced on both strands using primers CTX-M-1seq-F and CTX-M-1seq-R (ABI 310 Genetic Analyzer; Applied Biosystems, Belgium). All the ESBL isolates were examined for additional resistance and antibiotic resistance genes and integrons by PCR with specific primers (Table S2 , available as Supplementary data at JAC Online), as described previously. 9, 10 All the isolates were also tested for plasmid-mediated quinolone resistance (PMQR) genes, and the products were sequenced on both strands using the following primers: qnrS1.seq1F, qnrS1.seq1R, qnrS1.seq2F and qnrS1.seq2R for the qnrS1 gene; and qnrB19.seq1F, qnrB19.seq1R, qnrB19.seq2F and qnrB19.seq2R for the qnrB19 gene. The list of primers for PMQR is shown in Table S1 . The nucleotide sequences of the complete bla CTX-M-1 (876 bp) , qnrS1 (657 bp) and qnrB19 (645 bp) genes have been submitted to GenBank (accession numbers HQ456393, HQ640661 and HQ640660, respectively). Identification of E. coli phylogenetic groups was performed using a multiplex PCR assay.
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PFGE and transferability of ESBL/quinolone resistance genes by conjugation
The isolates were typed by XbaI-PFGE following CDC guidelines. 12 The transferability of bla genes and quinolone resistance genes was tested by conjugation. Plate-mating experiments were performed using plasmid-free, rifampicin-and nalidixic acid-resistant or, in the case of quinolone resistance, rifampicin-and sodium azide-resistant E. coli MT102RN and Salmonella enterica subsp. enterica serovar Typhimurium SL5325 as recipients. 13 
Plasmid characterization
Plasmid DNA from E. coli was isolated by the alkaline extraction procedure.
14 Plasmid DNA was introduced to competent E. coli DH5a or E. coli Top10 (both Invitrogen, USA) by chemical transformation, followed by selection of transformants on brain heart infusion agar supplemented with cefotaxime (2 mg/L) or ciprofloxacin (0.05 mg/L), respectively. The presence of a relevant bla gene/quinolone resistance gene in the transformants was confirmed by PCR. All transformants, transconjugants and their corresponding donors were examined for MICs of ciprofloxacin and nalidixic acid using an agar dilution method following CLSI guidelines. 7 The presence of a Tn3-like transposon in qnrS1-positive transformants was tested by PCR. 15 The size of the plasmid with the ESBL gene from transformants or transconjugants was designated by S1 nuclease PFGE. 16 Plasmid DNA from transformants/transconjugants was digested with EcoRV and HincII before gel electrophoresis in 1% agarose gel for 16 h at 67 V/cm. Plasmids were replicon typed as described previously. 17 
Statistical analysis
All data were used to calculate the prevalence of antimicrobial resistance and analysed by the x 2 test. Differences with P≤ 0.05 were considered significant.
Results
Equine clinic
Isolation of ESBL-producing E. coli
From the total of 37 horse faecal samples, 12 (32%) ESBLproducing E. coli isolates were found (Table 1) . Seventeen (34%) out of 50 isolates from the stables environment, 33 (18%) of samples from 179 flies and 1 (8%) of 12 rectal swabs from clinic staff were positive for ESBL -producing E. coli. Isolates belonged to phylogenetic groups A (20), B1 (40) and B2 (3).
Distribution of ESBL isolate pulsotypes
The total 64 ESBL-producing E. coli isolates thus obtained were compared using PFGE. These were isolates from horse faeces (12 isolates), the stables environment (17), clinic staff (1), the wound infection (1) and flies (33). The isolates were divided into 20 different pulsotypes designated with letters A-U (Tables 1 and 2 ). All except for two E. coli isolates acquired from horses during the sampling period showed unique PFGE profiles. Isolates with the same PFGE profile (designated A) were found in one horse, a staff member and several surface swabs, suggesting clonal dissemination of this isolate in the equine clinic during the period investigated. Most E. coli isolates from flies showed pulsotype G, which was not detected in horse and stables environment samples. However, several isolates from flies did show identical pulsotypes, as did a horse isolate (pulsotype N) and three stables environment isolates (pulsotypes N, O and R). The wound infection E. coli isolate 63743 showed the same pulsotype (S) as four fly isolates.
Antibiotic resistance genes and integrons in ESBL isolates
All the ESBL isolates were multiresistant, with resistance to 7 -12 of the antimicrobial agents tested, and their ESBL phenotype was caused by the presence of the gene bla CTX-M-1 . No bla TEM and bla SHV ESBL genes were detected. Additional resistance to chloramphenicol, gentamicin, streptomycin, sulphonamides and tetracycline was detected in all isolates, and all the isolates were positive for the catA1, strA, sul2 and tet(B) genes. Most isolates also contained class 1 integrons with variable gene cassettes. A 1.7 kb integron with dfrA17-aadA5 was most prevalent, followed by a 1.6 kb integron with dfrA12-aadA2 and a 1.5 kb integron with dfrA1-aadA1. Class 2 integrons (2.5 kb in size) with the dfrA1-sat-aadA1 cassette were also found. All the ESBL-positive isolates were examined for plasmid-mediated Inc, incompatibility group; AR, antibiotic resistance. a X, catA1, strA, sul2, tet(B), I1a, sul1, int1, class 1 integron 1.6 kb: dfrA12-aadA2; I1a 1 , int1, dfrA12-aadA2 (PCR for variable region of integron using 5CS-3CS primers was negative); I1b, sul1, int1, class 1 integron 1.5 kb: dfrA1-aadA1; I1c, sul1, int1, class 1 integron 1.7 kb: dfr1A17-aadA5; I1d, sul1, int1, dfrA1-orf-aadA5 (PCR for variable region of integron using 5CS-3CS primers was negative); I2, int2, class 2 integron 2 kb: dfrA1-sat-aadA1. quinolone resistance genes. In 11 isolates from the stables environment (n ¼4), horse faeces (n¼ 4), flies (n¼ 2) and wound infection (n¼ 1), the genes qnrS1 and/or qnrB19 were detected ( Table 2) .
Analysis of ESBL plasmids
The gene bla CTX-M-1 was transferred to E. coli by conjugation, but it was not transferred to Salmonella. Most of the transconjugants contained a large plasmid of 235 kb in size. In the isolates of pulsotype O and pulsotype S (strain 63743 from the wound infection), respectively, larger plasmids of 265 and 285 kb in size were detected. Plasmids of all sizes belonged to the IncHI1 group, and additional antibiotic resistance genes catA1, strA, sul2 and tet(B) were found to be co-located on this plasmid along with bla CTX-M-1 using PCR. Restriction fragment length polymorphism (RFLP) analysis of IncHI1 plasmids was performed only in 10 transconjugants, because of unsuccessful isolation of large plasmid DNA. Using EcoRV digestion, most plasmids showed an identical pattern (n¼ 9, profile V) or a several band difference was found (n¼ 1, profile V 1 ).
Characterization of plasmids harbouring qnr genes
The transferability of the qnr genes was tested and the plasmids carrying the qnr genes were analysed in all 11 qnr-positive isolates (Table 3 ). In most of the isolates, the qnr genes were transferred to E. coli and Salmonella by conjugation. Chemical transformation of a qnr-carrying plasmid was successful in most of the isolates. The MICs of nalidixic acid and ciprofloxacin for donor strains, transconjugants and transformants are shown in Table S3 (available as Supplementary data at JAC Online). The qnr genes were located on plasmids of 40 or 45 kb in size. All the plasmids with qnrB19 belonged to incompatibility group IncN and had the same RFLP profiles. Plasmids with the qnrS1 gene also showed the same indistinguishable RFLP profiles (in one isolate a two band difference was found of type Ia) and belonged to the IncX1 group. The gene bla TEM-1 and a Tn3-like transposon were found to be located on this IncX1 plasmid. In the isolate from the wound infection, the qnrS1 gene was located on a large IncHI1/X1 plasmid of 285 kb in size, together with the bla CTX-M-1 , bla TEM-1 , catA1, strA, sul2 and tet(B) genes, although the PCR for Tn3-like transposon was negative.
Excretion of ESBL-producing E. coli in the horse faeces
Concentrations of ESBL-producing E. coli isolates ranged from 8.18×10 3 to 7.73×10 6 cfu per gram of horse faeces.
Horseback riding centre
Isolation of ESBL-producing E. coli
From the samples taken during the first sampling, we isolated ESBL-positive E. coli from faeces of four (9%) of the horses examined. These samples originated from the mother of the antibiotic-treated foals (sample no. KK6) and from the horses stabled in the neighbouring boxes (KK4, KK5 and KK8). Of 20 samples examined from the waterers, ESBL-positive E. coli were detected in two (10%) boxes (NK6 and NK7), one of which belonged to the mother of the antibiotic-treated foals (NK6).
The following two samplings resulted in no ESBL-positive E. coli detection ( Table 1 ).
Characterization of ESBL-producing E. coli isolates
All the ESBL-positive isolates were multiresistant, with resistance to five to nine of the antibiotics tested, and were positive for the bla TEM-1 and bla CTX-M-1 genes. The isolates belonged to phylogenetic group B1. Class 2 integrons of 2.5 kb in size with dfrA1-sat-aadA1 gene cassettes were found in all of the isolates 
NT, not tested; AR, antibiotic resistance; X, catA1, strA, sul2, tet(B).
All of the qnr-positive isolates carried bla CTX-M-1 on a 235 kb plasmid (apart from 63743). RFLP profile determined by EcoRV and HincII digestion.
Antibiotic-resistant E. coli in horses 761 JAC (Table 2) . Most of the ESBL-positive E. coli isolates showed unique PFGE profiles. The gene bla CTX-M-1 was transferred to E. coli by conjugation, but it was not transferred to Salmonella. The bla CTX-M-1 gene was localized on a small (30 kb) IncN plasmid (n¼ 6) or on an 85 kb IncI1 plasmid along with the streptomycin resistance gene aadA1. All the plasmids of the IncN group showed the same restriction profile. No qnr genes were found in these ESBL-producing E. coli isolates.
Statistical analysis
The prevalence of ESBL-producing E. coli in horses and environmental smears at the equine clinic was significantly higher (P,0.001) than in horses and environmental smears at the horseback riding centre.
Discussion
We consider the common finding of ESBL-positive and fluoroquinolone-resistant isolates with plasmid -mediated qnr genes among E. coli isolates in horses at two horse facilities alarming. Cephalosporins are important antibiotics in both human and veterinary medicine. In horses, third-and fourthgeneration cephalosporins are advised, with specific cautions, only for the treatment of foal septicaemia. 18 Our results showed that this therapeutic intervention in the riding centre implicated the excretion of ESBL-producing E. coli by the mother of the antibiotic-treated foals and by the horses from the neighbouring boxes, as well as the contamination of the stables environment. No ESBL-producing E. coli strains were detected during the following two samplings in May and June, which indicates a temporary colonization of these horses by ESBL-producing strains, probably as a result of cephalosporin selective pressure. High prevalence of antimicrobial-resistant isolates from hospital-treated horses compared with untreated and a non-hospitalized community group of horses has been documented. 2 High risk for faecal carriage of resistant E. coli in horses during hospitalization has been recently identified. 19 This includes a high prevalence of ESBL-producing E. coli in faecal samples of hospitalized horses, with a significantly increased prevalence during hospitalization compared with at time of admission. We assume that the effect of hospitalization on colonization by antibiotic-resistant bacteria in horses has also played an important role in our study. At the equine clinic, various antibiotics, including small portions of extendedspectrum cephalosporins, were used for therapy of horses. Metronidazole, sulphonamides, aminoglycosides and fluoroquinolones were the antibiotics with the highest consumption. It appears that co-selection promoted by the usage of these non -b-lactam antibiotics is the reason for the high prevalence of multidrug-resistant ESBL isolates in horses.
The horse colon can provide an environment suitable for the survival and propagation of the causative agents for nosocomial infections. 20 The high concentrations of E. coli isolates in horse faeces detected in our study markedly increase environmental contamination and enable subsequent colonization of other species, such as flies, occurring in the contaminated environment. Our results indicate a high level of contamination of the stables environment, which affected colonization of flies by ESBL-producing E. coli. Such colonized flies can further serve as vectors of resistant bacterial strains. A high prevalence of antibiotic-resistant E. coli strains has been observed in flies captured on cattle and pig farms. 21, 22 In our study, the same PFGE profiles were occasionally observed in E. coli from horses, environmental samples and flies, indicating a role for clonal spreading of some strains. However, the high genetic diversity observed among bla CTX-M-1 -positive E. coli isolated from horses, the stables environment and flies indicated that the spread of isolates harbouring the gene bla CTX-M-1 within the equine clinic resulted not only from clonal dissemination, but that horizontal gene transfer is also involved in the dissemination of ESBL-positive E. coli at the equine clinic. This was confirmed by the plasmid analysis. Clonal spread of bla CTX-M-1 -positive E. coli, as well as horizontal gene transfer of bla CTX-M-1 , was also demonstrated at the riding centre. The same observation has been made in hospitalized horses in the UK. 19 Various associations among the plasmids and b-lactamase genes have been observed. In the present study, bla CTX-M-1 was harboured on conjugative plasmids of three different incompatibility groups-IncN, IncI1 and IncHI1. 23, 24 Our study provides the first demonstration of an association between ESBL-encoding genes and large IncHI1 multiresistance plasmids. Large plasmids (usually .160 kb) of incompatibility group HI1 are important vectors of antibiotic resistance in both major causal agents of enteric fever (Salmonella Typhi and Salmonella Paratyphi A). 25 It has been demonstrated that these IncHI1 plasmids allow major human pathogens to acquire genes available in the environment and in the human gut, and that they are maintained by enhancing the competitive advantage of the bacterial host. 26 Association of IncHI1 plasmids with antibiotic resistance to chloramphenicol, tetracycline, aminoglycosides and sulphonamides, and relevant genes [catA1, tet(B), strA and sul2] has been demonstrated. 27 High prevalence of qnr genes has been described in E. coli isolates carrying other resistance determinants, such as ESBLproducing strains, probably due to co-transfer in the same genetic elements. 28 In our study, qnrS1 and qnrB19 genes carried by plasmids of the IncN and IncX1 incompatibility groups were detected in multiresistant ESBL-producing E. coli from horses, surface environmental samples and flies at the equine clinic. The qnrS1 gene has been recently detected also on a 45 kb non-conjugative IncX1 plasmid in one poultry E. coli isolate in Italy and, similar to in our study, the qnrS1 gene in this poultry isolate was associated with a Tn3-like transposon containing the bla TEM-1 gene. 29 IncX1 plasmids have recently also been found to be associated with ESBL genes, such as bla This study illustrates that ESBL-producing E. coli, as well as plasmids carrying ESBL genes of clinical interest, can be easily transferred among horses, humans and flies living in close contact. The presence of ESBL-producing and fluoroquinoloneresistant bacteria in the horse hospital environment increases the health risk and raises essential questions about the control of nosocomial infections. The results of the presented study indicate the essential importance of infection control strategies, such as frequent hand hygiene, barrier nursing, and proper cleaning and disinfection. Such practices should minimize the spread of antibiotic-resistant bacteria as well as of mobile genetic determinants harbouring antibiotic resistance genes in a hospital environment. 30 Dolejska et al.
